EquityZen Growth Technology Fund LLC - Series 2184
Raised
$2M
Investors
70
Min Invest
$3,007
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 2184 is a Delaware LLC filed by EquityZen Advisors on 2025-11-26, raising $2.5M from 70 investors under Rule 506(b) and Section 3(c)(1). The offering has a $3K minimum investment and is part of EquityZen's platform of pre-IPO secondary market vehicles, one of approximately 1,889 related EDGAR entities.
This pre-IPO pooled investment fund uses the standard 506(b)/3(c)(1) private placement structure common to secondary market platforms. The $3K minimum represents a retail-accessible tier relative to typical pre-IPO vehicles, and the 70-investor count with $2.5M raise indicates an average commitment of approximately $36K per participant.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Phil Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
